Literature DB >> 32606193

Quantitative Assessment of Interim PET/CT Could Have More Prognostic Relevance than Visual Assessment for Predicting Clinical Outcome of Extranodal Diffuse Large B Cell Lymphoma.

Dong Won Baek1, Hee Jeong Cho1, Ju-Hyung Kim1, Sang Kyun Sohn1, Ga-Young Song2, Seo-Yeon Ahn2, Sung-Hoon Jung2, Jae Sook Ahn2, Je-Jung Lee2, Hyeoung-Joon Kim2, Shin-Young Jeong3, Chae Moon Hong3, Jung-Joon Min4, Joon-Ho Moon5, Deok-Hwan Yang6.   

Abstract

BACKGROUND/AIM: The present study retrospectively investigated the predictive accuracy of interim positron emission tomography/computed tomography (iPET/CT) based on the Deauville 5-point scale (5-PS) and a quantitative SUV-based assessment in patients with extranodal (EN) diffuse large B cell lymphoma (DLBCL). PATIENTS AND METHODS: The Deauville 5-PS and the SUVmax reduction (ΔSUVmax) assessment for interpreting the response to iPET/CT were used.
RESULTS: A total of 163 patients were enrolled in this study. With a median follow-up of 52.5 months, ΔSUVmax successfully predicted the survival outcomes of patients with one extranodal (EN) involvement in terms of overall survival (OS) (p=0.012) and progression-free survival (PFS) (p<0.001). Visual assessment using the Deauville 5-PS did not predict survival outcomes in patients with one or more EN involvements in terms of OS and PFS.
CONCLUSION: The quantitative SUV-based assessment with iPET/CT was a significant prognosticator for long-term survival outcomes, especially in patients with one EN involvement. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  DLBCL; Deauville 5-point scale; SUV; extranodal; interim PET/CT

Mesh:

Substances:

Year:  2020        PMID: 32606193      PMCID: PMC7439899          DOI: 10.21873/invivo.12018

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  38 in total

1.  Rituximab plus CHOP for diffuse large-B-cell lymphoma.

Authors:  Saad Akhtar; Irfan Maghfoor
Journal:  N Engl J Med       Date:  2002-06-06       Impact factor: 91.245

2.  Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP.

Authors:  Changhoon Yoo; Dae Ho Lee; Jeong Eun Kim; Jungmin Jo; Dok Hyun Yoon; Byeong Seok Sohn; Sang-We Kim; Jung-Shin Lee; Cheolwon Suh
Journal:  Ann Hematol       Date:  2010-12-22       Impact factor: 3.673

3.  Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis.

Authors:  Chieh Lin; Emmanuel Itti; Corinne Haioun; Yolande Petegnief; Alain Luciani; Jehan Dupuis; Gaetano Paone; Jean-Noël Talbot; Alain Rahmouni; Michel Meignan
Journal:  J Nucl Med       Date:  2007-09-14       Impact factor: 10.057

4.  Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy.

Authors:  Emmanuel Itti; Chieh Lin; Jehan Dupuis; Gaetano Paone; Daniela Capacchione; Alain Rahmouni; Corinne Haioun; Michel Meignan
Journal:  J Nucl Med       Date:  2009-03-16       Impact factor: 10.057

5.  Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project.

Authors:  Anamarija M Perry; Jacques Diebold; Bharat N Nathwani; Kenneth A MacLennan; Hans K Müller-Hermelink; Martin Bast; Eugene Boilesen; James O Armitage; Dennis D Weisenburger
Journal:  Haematologica       Date:  2016-06-27       Impact factor: 9.941

Review 6.  Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: do we trust the driver?

Authors:  Steven Le Gouill; René-Olivier Casasnovas
Journal:  Blood       Date:  2017-04-17       Impact factor: 22.113

7.  Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.

Authors:  Craig H Moskowitz; Heiko Schöder; Julie Teruya-Feldstein; Camelia Sima; Alexia Iasonos; Carol S Portlock; David Straus; Ariela Noy; Maria L Palomba; Owen A O'Connor; Steven Horwitz; Sarah A Weaver; Jessica L Meikle; Daniel A Filippa; James F Caravelli; Paul A Hamlin; Andrew D Zelenetz
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

8.  Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.

Authors:  Malik E Juweid; Gregory A Wiseman; Julie M Vose; Justine M Ritchie; Yusuf Menda; James E Wooldridge; Felix M Mottaghy; Eric M Rohren; Norbert M Blumstein; Alan Stolpen; Brian K Link; Sven N Reske; Michael M Graham; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2005-04-18       Impact factor: 44.544

Review 9.  Limitations of PET for imaging lymphoma.

Authors:  Sally F Barrington; Michael J O'Doherty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-13       Impact factor: 9.236

Review 10.  The predictive value of interim and final [18F] fluorodeoxyglucose positron emission tomography after rituximab-chemotherapy in the treatment of non-Hodgkin's lymphoma: a meta-analysis.

Authors:  Yuyuan Zhu; Jianda Lu; Xin Wei; Shaoli Song; Gang Huang
Journal:  Biomed Res Int       Date:  2013-08-14       Impact factor: 3.411

View more
  1 in total

1.  Diagnostic Accuracy and Prognostic Relevance of Immunoglobulin Heavy Chain Rearrangement and 18F-FDG-PET/CT Compared With Unilateral Bone Marrow Trephination for Detecting Bone Marrow Involvement in Patients With Diffuse Large B-Cell Lymphoma.

Authors:  Mihee Kim; Seo-Yeon Ahn; Jae-Sook Ahn; Ga-Young Song; Sung-Hoon Jung; Je-Jung Lee; Hyeoung-Joon Kim; Jun Hyung Lee; Myung-Geun Shin; Sang Yun Song; Deok-Hwan Yang
Journal:  J Korean Med Sci       Date:  2022-01-03       Impact factor: 2.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.